The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as mono...

Full description

Saved in:

Bibliographic Details
Published in:	Journal for immunotherapy of cancer 2019-12, Vol.7 (1), p.354-20, Article 354
Main Authors:	Rini, Brian I., Battle, Dena, Figlin, Robert A., George, Daniel J., Hammers, Hans, Hutson, Tom, Jonasch, Eric, Joseph, Richard W., McDermott, David F., Motzer, Robert J., Pal, Sumanta K., Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.
Format:	Article
Language:	eng
Subjects:	Antibodies Antimitotic agents Antineoplastic agents Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Avelumab Axitinib Biomarkers Biomarkers, Tumor Cancer Cancer therapies Cancer treatment Carcinoma Carcinoma, Renal cell Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - etiology Carcinoma, Renal Cell - pathology Care and treatment Clinical trials Committees Conflicts of interest Death Disclosure Disease Management Drug therapy Endothelial growth factors Evidence-based medicine FDA approval Guidelines Guidelines and Consensus Statements Humans Immune checkpoint inhibitor (ICI) Immunotherapy Ipilimumab Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - etiology Kidney Neoplasms - pathology Literature reviews Metastasis Molecular Targeted Therapy Monoclonal antibodies Neoplasm Staging Nivolumab Patients Pembrolizumab Phenols (Class of compounds) Position and Guidelines Position Article and Guidelines Practice Guidelines as Topic Questionnaires Renal cell carcinoma Renal cell carcinoma (RCC) Sunitinib Targeted cancer therapy Tyrosine Vascular endothelial growth factor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.
ISSN:	2051-1426 2051-1426